ADRX-0405

Adcentrx Therapeutics has commenced patient dosing in a phase 1a/b clinical trial for ADRX-0405, a novel antibody-drug conjugate targeting STEAP1, aimed at treating advanced solid tumours. This marks a significant step in the development of targeted therapies for cancers expressing STEAP1, such as metastatic castration-resistant prostate cancer.

Adicet Bio's ADI-001 receives FDA Fast Track designation for refractory systemic lupus erythematosus (SLE) with extrarenal involvement, expediting its development.

Adcendo's ADCE-D01, a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, has received FDA clearance for a Phase I/II trial in metastatic and/or unresectable soft tissue sarcoma (STS).